ACRX Nears D-day, TRVN On Watch, All's Well With CRSP, TearLab Disappointed

Today's Daily Dose brings you news about FDA staffers' comments on AcelRx Pharma's pain drug candidate Dsuvia; Audentes Therapeutics' stock offering; FDA lifting clinical hold on CRISPR Therapeutics' investigational drug; TearLab's disappointment, and Trevena's much-awaited regulatory catalyst.

from RTT - Biotech https://ift.tt/2CBA8GC
via IFTTT